2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 10 2.3 Etiology 10 2.4 Pathophysiology 10 2.5 Diagnosis 11 2.5.1 Physical Examination 11 2.5.2 Blood Tests 11 2.5.3 1987 Rheumatoid Arthritis Classification 12 2.5.4 The 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 12 2.6 Epidemiology 13 2.7 Co-morbidities and Complications 13 2.8 Disease Progression 14 2.9 Pharmacotherapy Algorithm 14 2.10 Treatment Options 16
View summary of this report @ http :// www . radiantinsights . com / research / rheumatoidarthritis-market-to-2020-a-crowded-market-characterized-by-modest-growth
2.10.1 Pharmacological 16 2.10.2 Methotrexate 16 2.10.3 Plaquenil ( hydroxychloroquine ) 16 2.10.4 Arava ( leflunomide ) 16 2.10.5 Azulfidine , Salazopyrin ( sulfasalazine ) 17 2.10.6 Neoral ( cyclosporine ) 17
2.10.7 Prograf ( tacrolimus ) 17
2.10.8 Xeljanz ( tofacitinib ) 17 2.11 Other Non-biologics 17
Follow Us :